DR Abernethy, JB Schwartz - New England Journal of Medicine, 1999 - content.nejm.org Drugs classified as calcium antagonists or calcium-channel blockers were
introduced into clinical medicine in the 1960s and are now among the most
frequently prescribed drugs for the treatment of cardiovascular diseases. 1 ... Cited by 238 - Related articles - BL Direct - All 5 versions
RF Vestal - Journal of the American Geriatrics Society, 1982 - ncbi.nlm.nih.gov 1: J Am Geriatr Soc. 1982 Mar;30(3):191-200. Pharmacology and aging. Vestal
RF. Publication Types: Review. Mesh Terms: Adult; Age ... Cited by 84 - Related articles - All 5 versions
K Turnheim - Drugs &# 38; Aging, 1998 - ingentaconnect.com Abstract Pharmacotherapy in the elderly requires an understanding of the
age-dependent changes in function and composition of the body. Aging is
characterised by a progressive loss of functional capacities of most if not ... Cited by 79 - Related articles - BL Direct - All 3 versions
J George, K Byth, GC Farrell - Biochemical pharmacology, 1995 - Elsevier Multivariate linear regression analysis was used to examine the influence of
age, gender and environmental variables on the hepatic content of cytochromes
P450 (CYP, P450) 1A2, 2C, 2E1 and 3A in 71 subjects; 21 with histologically ... Cited by 74 - Related articles - All 4 versions
ME Krecic-Shepard, CR Barnas, J Slimko, MP … - The Journal of Clinical Pharmacology, 2000 - jcp.sagepub.com V erapamil is a commonlyprescribed calcium chan- nel blocker for the management
of patients with cardiovascular disease. Verapamil undergoes exten- sive
first-pass elimination and is both a cytochrome P450 (CYP) 3A and ... Cited by 59 - Related articles - BL Direct - All 7 versions
NM Kaplan - Jama, 1989 - Am Med Assoc Calcium entry blockers will be increasingly used for the treatment of
hypertension. The currently available calcium entry blockers are similar in
antihypertensive efficacy but differ in their effects on the ... Cited by 59 - Related articles - All 6 versions
G Mikus, M Eichelbaum, C Fischer, S Gumulka … - Journal of Pharmacology and Experimental …, 1990 - ASPET ABSTRACT The pharmacokinetics, metabolism and pharmacodynamics of verapamil (160
mg po of a pseudoracemic mixture) were eval uated in six healthy volunteers
before and after coadministration of cimetidine (400 mg bid). Enantiomers ... Cited by 56 - Related articles - All 3 versions
DDS LaDeane Fattore, DDS Michael Stablein … - Special Care in Dentistry - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 42 - Related articles - All 2 versions
MF Fromm, K Dilger, D Busse, HK Kroemer, M … - British journal of clinical pharmacology, 1998 - pubmedcentral.nih.gov Eight older subjects (67.1±1.2 years mean±sd) received racemic, unlabelled
verapamil orally for 16 days (120 mg twice daily). Rifampicin (600 mg daily) was
coadministered from day 5 to 16. Using stable isotope technology (ie ... Cited by 34 - Related articles - BL Direct - All 5 versions
- ►nih.gov [PDF] SK Gupta, L Atkinson, T Tu, JA Longstreth - British journal of clinical pharmacology, 1995 - pubmedcentral.nih.gov 1 Pharmacokinetics and pharmacodynamics of R- and S-verapamil and R- and S-
norverapamil were studied at steady state following administration of 180 mg
verapamil delivered by a controlled-release gastrointestinal therapeutic ... Cited by 26 - Related articles - BL Direct - All 4 versions
